The cholesterol story

Cholesterol is used by the body to maintain cell structure. It is manufactured by the liver (although some additional cholesterol finds its way into the body from the food we eat). Cholesterol circulates in the blood via a process of cholesterol influx and efflux.1

Any imbalance between cholesterol influx and efflux can cause excess cholesterol to build up in the artery walls, leading to the development of plaque.2

What is cholesterol efflux?

As cholesterol cannot be broken down by the body, it relies on cholesterol efflux to remove cholesterol accumulated in arterial plaque. It is an essential process in which apolipoprotein A-I (ApoA-I) plays a crucial role.1,3-6

ApoA-I mediated

Cholesterol efflux occurs when cholesterol is transferred from macrophages within the arterial plaque to ApoA-I, the key functional component of high-density lipoproteins (HDL).3–7

ApoA-I is produced in the liver and intestines and secreted into plasma in lipid-poor form.4,5

High-density lipoproteins

Cholesterol efflux may help encourage plaque regression as excess cholesterol from macrophages within arterial plaque is transferred to ApoA-I in HDL.4,5

These cholesterol-enriched HDL particles then transport the cholesterol to the liver where it may be excreted either as free cholesterol or after conversion to bile acids.1

Low-density lipoproteins

Cholesterol influx works in the opposite direction and may promote plaque formation, with low-density lipoprotein (LDL) moving cholesterol from the liver and intestines to the heart.3,7

Adapted from Pepine et al. 19988

Discover the importance of cholesterol efflux

This video provides a visual overview of the important role of cholesterol efflux in the prevention of plaque development.

Continue to

Impact of low cholesterol efflux

Understand why a continued reduction in already impaired cholesterol efflux directly after an AMI increases the risk of a recurrent CV event4,9–13

What happens to cholesterol efflux after an AMI?

Learn about why patients are at a disproportionately high risk in the 90-day period post AMI13–17

Current standard of care post AMI

Current standard of care and newer therapies have lowered the long-term risk of recurrent CV events; however, data show that patients are still at risk during the 90-day high-risk period after an AMI18–25

Get the latest news

Sign up to receive news alerts and information about educational resources to help your patients through the 90-day high-risk period post AMI

By submitting this form, you are consenting to disclose any information provided, including your name, email address, telephone number, and any other information (collectively “Personal Information”) to CSL Behring and its representatives, agents, and contractors, including CSL Behring’s support program(s) (collectively “CSL Behring Entities”) and to receive communications with relevant information from CSL Behring Entities. You may be contacted by mail, email, telephone, and/or SMS/text message in relation to our business, products, services, and educational programs intended to benefit patients using or eligible to use CSL Behring therapies. You will have the ability to opt-out from receiving communications from CSL Behring Entities at any time. CSL Behring and CSL Behring Entities will not sell your personal information. CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy


AMI, acute myocardial infarction; ApoA-I, apolipoprotein A-I; CV, cardiovascular; HDL, high-density lipoprotein; LDL, low-density lipoprotein


1. Angelin B et al. Atheroscler Suppl 2002; 3:23–30.

2. Bentzon JF et al. Circ Res 2014; 114:1852–1866.

3. Kingwell BA, Chapman MJ. Circulation 2013; 128:1112–1121.

4. Rader DJ et al. J Lipid Res 2009; 50 Suppl:S189–S194.

5. Rader DJ, Hovingh GK. Lancet 2014; 384:618–625.

6. Rosenson RS et al. Circulation 2012; 125:1905–1919.

7. Estrada-Luna D et al. Molecules 2018; 23:2730.

8. Pepine CJ. Am J Cardiol 1998; 82:23S–27S.

9. Ray KK et al. Eur Heart J 2014; 35:1792–1800.

10. Soares AAS et al. Clin Chim Acta 2018; 478:51–56.

11. Ross R. N Engl J Med 1999; 340:115–126.

12. Saleheen D et al. Lancet Diabetes Endocrinol 2015; 3:507–513.

13. Rohatgi A et al. N Engl J Med 2014; 371:2383–2393.

14. Piepoli MF et al. Eur J Prev Cardiol 2016; 23:1994–2006.

15. Chi G et al. Clin Cardiol 2022; 45:299–307.

16. Guerin M et al. J Am Coll Cardiol 2018; 72:3259–3269.

17. Zhang J et al. Am J Cardiol 2016; 117:508–514.

18. Schwartz GG et al. N Engl J Med 2018; 379:2097–2107.

19. Cannon CP et al. N Engl J Med 2015; 372:2387–2397.

20. Schwartz GG et al. JAMA 2001; 285:1711–1718.

21. Bhatt DL et al. N Engl J Med 2019; 380:11–22.

22. Bhatt DL et al. J Am Coll Cardiol 2019; 73:2791–2802.

23. Mehta SR et al. N Engl J Med 2019; 381:1411–1421.

24. Wallentin L et al. N Engl J Med 2009; 361:1045–1057.

25. Nair R et al. J Am Heart Assoc 2021; 10:e019270.


USA-GEN-0051 | October 2022